Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan.

However, the difference among the three groups did not reach statistical significance (Log-rank p = 0.055) ( Figure 2 ).

also in 111,027 other papers

In the phase IIB LUX-Lung 7 trial, Afatinib demonstrated superior progression-free survival (PFS) compared to first-generation Gefitinib in the first-line treatment of advanced NSCLC with EGFR mutations, along with a slight trend toward improved overall survival (OS) [ 15 , 16 ].

also in 4,078 other papers

The sequential use of Afatinib followed by Osimertinib showed a trend toward improved OS, highlighting the importance of rebiopsy for identifying T790M mutations to guide subsequent therapy.

also in 53,322 other papers